With FLAURA (osimertinib alone), FLAURA2 (osimertinib with chemotherapy), and MARIPOSA (amivantamab plus lazertinib) all now FDA approved 1L options for #EGFR NSCLC, how do we select the optimal regimen? Drs. Natasha Leighl, Tom Newsom-Davis and I discuss. iaslc.org/iaslc-news/lun…

It was a great pleasure to be here in Dresda at Jakob Nikolas Kather lab. He organized an impressive summer school on #AI in #medicine and Oncology! Looking forward to organize more and more educational events! #Oncologist4Tech

Do you want to elevate your Science Communications during WCLC24? Join us for the IASLC Communications Committee Workshop on Saturday, Sept. 7 (14:30-16:30 PT) – Room 26B. You will engage in a lively discussion, network, and exchange ideas with peers! IASLC #WCLC24

Don’t miss IASLC 50th birthday at WCLC24 - Dr. Estela Rodriguez IASLC oncodaily.com/blog/129517 #Cancer #IASLC #LungCancer #OncoDaily #WCLC24

Thrilled to participate on this all-star panel of amazing friends and leaders! I'll be joined by Rajika Jindani, MD, MPH, MS, a surgical resident at Montefiore Health System Albert Einstein College of Medicine - Official who I am grateful to sponsor & mentor, as we focus on supporting the Next Generation and the call to "Sponsor Her".

🚨🥁 Hot off the press 👉 Presenting to the world a future framework for Tissue agnostic drug development - Special article published Annals of Oncology –an X 'torial for this major milestone in #precisionMedicine ✅1/n - “The ESMO Tumour-Agnostic Classifier and Screener

Advances in precision medicine led to approval of tumour-agnostic molecularly guided therapies. The minimum requirements for claiming tumour-agnostic potential remain elusive. Different scenarios of minimum ORR, number of tumour types investigated & number of evaluable patients

🔥Ph III KN867 trial of SBRT+concurrent/adjuvant pembrolizumab stopped early due to higher AEs in IO arm, &lack of EFS&OS benefit Important negative data, that will inform optimum timing of IO, & definitive tx modality Lets see the data OncoAlert #LCSM merck.com/news/merck-pro…

🫁 NCCN guideline. - NSCLC updated 🫁 🌟 Version 8.2024 — August 23, 2024

Honored to speak at the IASLC World Lung Cancer Conference in San Diego, Sept 7-10, on "Targeted Therapies for NSCLC – The Patient’s Perspective." Proud to join a global team dedicated to advancing #lungcancer care. 💪#WCLC2024 #IASLC50 #FairLifeLCC #patientadvocacy #IASLC

Out now our review on #BispecificAntibodies Trends in Cancer!👉t.ly/L0BS0 We cover preclinical & clinical developments, trials data & challenges ahead A joy working w the dream team! Mercedes Herrera Giulia Pretelli Thiago M Steiner Lillian Siu Elena Garralda Jayesh Desai

IMO this adds to the mount of evidence that concurrent RT/IO is not always better compared to sequential RT ➡️IO and can even be detrimental , as we also saw in PACIFIC-2 for st3. Would it have been different if trial design gave Pembro ONLY AFTER SBRT? Wonder how this will

Learn from our local host Sandip Patel MD #WCLC24

This will be a great opportunity to share ideas on the subject of ADCs, as there are still so many questions on the best approach to ADCs in the lung field... a wave that will continue...#wclc24 Stephen V Liu, MD

Not to mention the “Similar topics that might be of interest to you” function to facilitate theme selection 😀 See you there everybody!! IASLC #WCLC24

Night Office View- only in San Diego!! IASLC #WCLC24

Good morning from beautiful San Diego, not too jet lagged!! 😁 Looking forward to a productive #WCLC24 put together by amazing colleagues including dear friends Narjust Florez, MD, FASCO and Sandip Patel MD and many many more and celebrating 50 years of IASLC 🎉